FXYD3通过与IRF7结合来促进瘤的进展,以调节JAK2 / STAT5信号在肝脏内胆管癌中的信号传递
Yan Zhou1,2, Xiaofeng Shen3, Shuo Zhang1,2
1Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210000, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|October 30, 2025
概括
通过激活免疫信号通路,FXYD3蛋白促进肝内胆管癌 (ICC) 的进展. 用一种新的纳米输送系统准FXYD3在治疗ICC和提高化疗有效性方面显示出前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 肝脏内胆管癌 (ICC) 的预后不好,特别是在不可手术的情况下.
- FXYD3是Na+/K+ ATPase家族中的调节剂,与各种癌症有关,但其在ICC中的作用尚不清楚.
- 了解ICC的致病性对于开发有效疗法至关重要.
研究的目的:
- 调查FXYD3在肝脏内胆管癌 (ICC) 进展中的作用.
- 阐明了FXYD3介导的ICC开发背后的分子机制.
- 评估针对性FXYD3纳米输送系统用于ICC治疗.
主要方法:
- 从ICC数据集中对单细胞转录组资料的生物信息分析.
- 在体外和体内实验验证FXYD3表达和功能的验证.
- 单细胞测序,空间转录组分析和分子相互作用测试.
- 在临床前ICC模型中评估针对性的FXYD3纳米输送系统 (siFXYD3@PEP).
主要成果:
- FXYD3在ICC组织中过度表达,并与瘤进展和不良预后有关.
- FXYD3与IRF7相互作用,通过cGAS/STING和JAK2/STAT5路径激活一个正反循环.
- 这种途径的激活驱动了ICC的恶性进展.
- 在ICC模型中,siFXYD3@PEP系统表现出显著的抗瘤作用和提高化疗灵敏度.
结论:
- FXYD3通过调节与癌症相关的炎症和先天性免疫信号,在ICC病变发生过程中发挥着关键作用.
- 准FXYD3为肝内胆管癌提供了一个新的治疗策略.
- 这些发现为了解ICC发展和治疗提供了新的框架.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K


